Taletrectinib is a targeted therapeutic agent for the treatment of ALK/ROS1 gene fusion-positive non-small cell lung cancer (NSCLC). It inhibits the growth of cancer cells by suppressing abnormal kinase activity. The medication must be used under the guidance of a physician. Common adverse reactions include edema, nausea, fatigue, etc. Regular monitoring of liver function and electrocardiographic parameters is required during treatment, and contraindicated populations must avoid its use.
Indications and Mechanism of Action
Taletrectinib is mainly indicated for the treatment of locally advanced or metastatic non-small cell lung cancer positive for ALK or ROS1 gene mutations. It selectively inhibits the activity of kinases such as ALK and ROS1, blocks abnormal signal transduction pathways, thereby inhibiting the proliferation of tumor cells and inducing apoptosis.
Dosage and Administration
Standard Dosage
The recommended dosage for adults is generally oral administration once daily, and the specific dosage shall be adjusted according to the patient's body weight, type of gene mutation and disease condition.
Administration Method
It can be taken on an empty stomach or after meals, but should be taken at a fixed time to maintain a stable plasma drug concentration. If a dose is missed, it should be taken as soon as possible before the next scheduled dose, and double dosing should be avoided.
Treatment Duration
Long-term continuous administration is required until disease progression or intolerable toxicity occurs. Do not discontinue the medication or adjust the dosage without medical advice.
Common Adverse Reactions
Mild Reactions
Edema (facial/extremity), nausea, diarrhea, fatigue, anorexia, etc. These can usually be relieved through symptomatic treatment.
Severe Reactions
Including interstitial lung disease, elevated liver enzymes, bradycardia, hyperglycemia, etc. Immediate discontinuation of the drug and medical attention are required in such cases.
Special Risks
Use during pregnancy may cause fetal malformations, and breastfeeding women need to suspend breastfeeding.
Precautions and Contraindications
Monitoring Requirements
Gene mutation status must be tested before treatment initiation; regular examinations of liver function, blood glucose, electrocardiogram and pulmonary imaging are required during treatment.
Drug Interactions
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin) should be avoided, as such combinations may affect the efficacy or toxicity of the drug.
Contraindicated Populations
It is contraindicated in patients with hypersensitivity to any ingredient of taletrectinib, those with severe hepatic insufficiency, and those with uncontrolled cardiovascular diseases.
Storage and Disposal
Storage Conditions
Store in a dark place below 30°C, keep in the original packaging to prevent moisture.
Disposal of Expired Drugs
Expired medications shall be disposed of in accordance with the specifications for medical waste to avoid environmental contamination.
The above information is for reference only. Specific medication shall be strictly followed under the guidance of a clinician, and the treatment regimen shall be adjusted according to individual conditions.
